EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:31772 - levobupivacaine hydrochloride (anhydrous)
| Formula | C18H28N2O.HCl |
| Net Charge | 0 |
| Average Mass | 324.896 |
| Monoisotopic Mass | 324.19684 |
| SMILES | CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl |
| InChI | InChI=1S/C18H28N2O.ClH/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H/t16-;/m0./s1 |
| InChIKey | SIEYLFHKZGLBNX-NTISSMGPSA-N |
| Roles Classification |
|---|
| Chemical Role: | amphiphile A surfactant molecule possessing both hydrophilic and lipophilic properties. |
| Biological Roles: | adrenergic antagonist An agent that binds to but does not activate adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. EC 3.1.1.8 (cholinesterase) inhibitor An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of cholinesterase (EC 3.1.1.8). EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor An EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that interferes with the action of Ca2+-transporting ATPase (EC 3.6.3.8). |
| Applications: | adrenergic antagonist An agent that binds to but does not activate adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. local anaesthetic Any member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) has part levobupivacaine(1+) (CHEBI:77458) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) has role adrenergic antagonist (CHEBI:37887) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) has role amphiphile (CHEBI:59941) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) has role EC 3.1.1.8 (cholinesterase) inhibitor (CHEBI:37733) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) has role EC 3.6.3.8 (Ca2+-transporting ATPase) inhibitor (CHEBI:60186) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) has role local anaesthetic (CHEBI:36333) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) is a 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride (CHEBI:77441) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) is enantiomer of dextrobupivacaine hydrochloride (anhydrous) (CHEBI:77442) |
| Incoming Relation(s) |
| bupivacaine hydrochloride (anhydrous) (CHEBI:31322) has part levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) |
| levobupivacaine hydrochloride hydrate (CHEBI:77453) has part levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) |
| dextrobupivacaine hydrochloride (anhydrous) (CHEBI:77442) is enantiomer of levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) |
| IUPAC Names |
|---|
| (2S)-1-butyl-2-[(2,6-dimethylphenyl)carbamoyl]piperidinium chloride |
| (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride |
| Synonyms | Source |
|---|---|
| (−)-bupivacaine hydrochloride | ChEBI |
| (S)-1-butyl-2',6'-pipecoloxylidide hydrochloride | ChEBI |
| levobupivacaine HCl | ChemIDplus |
| levobupivacaine hydrochloride | ChEBI |
| levobupivacaine monohydrochloride | ChEBI |
| Brand Name | Source |
|---|---|
| Chirocaine | ChEBI |
| Registry Numbers | Sources |
|---|---|
| Reaxys:8879953 | Reaxys |
| CAS:27262-48-2 | ChemIDplus |
| CAS:27262-48-2 | KEGG DRUG |
| Citations |
|---|